Provided by Tiger Fintech (Singapore) Pte. Ltd.

Royalty Pharma plc

34.84
-0.4300-1.22%
Post-market: 34.860.0190+0.05%18:52 EDT
Volume:3.53M
Turnover:123.05M
Market Cap:14.68B
PE:14.21
High:35.38
Open:35.09
Low:34.72
Close:35.27
Loading ...

Royalty Pharma announces R&D funding collaboration with Biogen

TIPRANKS
·
12 Feb

Royalty Pharma : Litifilimab Is Currently in Phase 3 Trials for Both Sle and Cle With Results Expected Between 2026 and 2027

THOMSON REUTERS
·
12 Feb

Royalty Pharma Announces R&D Funding Collaboration With Biogen

THOMSON REUTERS
·
12 Feb

Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

GuruFocus.com
·
12 Feb

Royalty Pharma PLC reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Feb

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
11 Feb

Royalty Pharma Q4 Net Income, Revenue Decrease

MT Newswires Live
·
11 Feb

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.9B-$3.05B, With Operating And Professional Costs Of Approximately 10% Of Portfolio Receipts And Interest Paid Of $260M

Benzinga
·
11 Feb

Earnings Flash (RPRX) Royalty Pharma Posts Q4 Net Income $208 Million

MT Newswires Live
·
11 Feb

Royalty Pharma Q4 2024 Adj EPS $1.16 Beats $1.05 Estimate, Sales $594.00M Miss $678.89M Estimate

Benzinga
·
11 Feb

Royalty Pharma Plc - 2025 Guidance: Portfolio Receipts Expected $2.9 Billion to $3.05 Billion

THOMSON REUTERS
·
11 Feb

Royalty Pharma Earnings: What To Look For From RPRX

StockStory
·
10 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
10 Feb

Is Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?

Simply Wall St.
·
09 Feb

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

THOMSON REUTERS
·
29 Jan

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

GlobeNewswire
·
29 Jan

Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%

Simply Wall St.
·
29 Jan

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

THOMSON REUTERS
·
29 Jan

Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?

Insider Monkey
·
23 Jan

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga
·
23 Jan